Chomariyati Alvi, Diansyah Muhammad Noor, Amrita Putu Niken Ayu, Romadhon Pradana Zaky, Yudho Bintoro Siprianus Ugroseno, Ashariati Ami, Savitri Merlyna
Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia.
Staff Member of Hematology and Medical Oncology Division, Department of Internal Medicine, Dr. Soetomo General Teaching Hospital, Surabaya, Indonesia.
Ann Med Surg (Lond). 2022 Jul 31;81:104300. doi: 10.1016/j.amsu.2022.104300. eCollection 2022 Sep.
Clinicians often encounter dilemma upon treating multiple primary malignancies.
We report a case of a female patient, 72, complained of a lump under her left eye since January 2019. Patient was diagnosed with infiltrating ductal carcinoma grade III of the right breast in June 2018 with ER+, PR+, and HER2-, treated with hormonal treatment. Histopathology examination of the lump revealed Non Hodgkin Lymphoma (NHL), B cell type, high grade. Patients received rituximab, cyclophosphamide, epirubicin, vincristin, and prednisone (RHCOP) for 6 cycles to overcome lymphoma then received hormonal therapy afterwards.
According to earlier published case reports, it's advised to start hormonal therapy after RHCOP. The survival time was 21 months (5.1-114.7 months) with 5-year overall survival 29.
Unfortunately, we could not have a follow-up on the patient after finishing 6 cycles of RHCOP due to the COVID-19 pandemic situation.
临床医生在治疗多种原发性恶性肿瘤时常常面临两难境地。
我们报告一例72岁女性患者，自2019年1月起主诉左眼下方有肿块。该患者于2018年6月被诊断为右乳腺浸润性导管癌III级，雌激素受体（ER）阳性、孕激素受体（PR）阳性、人表皮生长因子受体2（HER2）阴性，接受了激素治疗。对肿块进行组织病理学检查发现为B细胞型高级别非霍奇金淋巴瘤（NHL）。患者接受了6个周期的利妥昔单抗、环磷酰胺、表柔比星、长春新碱和泼尼松（RHCOP）方案治疗以控制淋巴瘤，之后接受了激素治疗。
根据早期发表的病例报告，建议在RHCOP方案治疗后开始激素治疗。生存时间为21个月（5.1 - 114.7个月），5年总生存率为29%。
不幸的是，由于新冠疫情，在完成6个周期的RHCOP方案治疗后我们无法对该患者进行随访。
